Business Wire

Investor Tej Kohli Expands ‘Venture Philanthropy’ Into 3d-printed Bionic Arms

29.11.2019 10:00:00 EET | Business Wire | Press release

Share

Investor Tej Kohli is to fund the purchase of ten bionic arms for children with limb differences in the UK. The Tej Kohli Foundation hopes that its commitment to fund arms for ten children over the next 5 months as part of its ‘Future Bionics’ program will highlight how assistive technology can substantially improve the lives and confidence of young people living with disabilities. The Tej Kohli Foundation hopes to inspire and influence other healthcare institutions to follow this lead and discover the advanced 3D-printed technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191128005558/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Tej Kohli Foundation co-Founder Wendy Kohli, Tilly Lockey wearing Open Bionics arms, Tej Kohli Foundation co-Founder Tej Kohli, future Hero Arm recipient Jacob Pickering, future Hero Arm recipient Harris Gribble (Photo: Business Wire)

In England the National Health Service (‘NHS’) currently provides a single-grip myoelectric-controlled (‘myo’) prosthesis at a cost of approximately £8,000. However, the Open Bionics Hero Arm can be controlled with the electrical signals generated by a user’s muscles and has superior multi-grip functionality that enables users to perform many more everyday activities.

The Open Bionics Hero Arm costs £10,000 through a private prosthetics clinic in the UK, whereas other advanced multi-grip bionic hands cost £30,000 - £60,000. The Tej Kohli Foundation will spend an initial £100,000 to launch its ‘Future Bionics’ programme, which will enable ten British children to access not just a superior technology, but a better life.

The first Hero Arm recipient is 10-year-old Jacob Pickering from Blackburn, who will receive his new Hero Arm just in time for Christmas. Jacob was born without his right arm as a result of amniotic band syndrome. All Jacob has spoken about for the past month is the Hero Arm, and his father David is “completely overwhelmed” that Jacob has been selected for a donation and claims that it will “change Jacob’s life”. The second Hero Arm recipient is 14-year-old Harris Gribble from Exeter, who is a keen Rugby and Cricket player.

The lightweight Hero Arm is currently the only multi-grip myo prosthetic arm that is available for paediatric use. The enhanced ability of the user to be able to personalise their 3D-printed Open Bionics Hero Arm is also a huge boost to mental well-being and to perceived social acceptance. This is particularly important for younger people.

Investor Tej Kohli first discovered Bristol-based Open Bionics when he invested into ‘Rewired’, a robotics-focused venture studio ‘with a humanitarian bent’ that was a very-early backer of Open Bionics in 2017.

Tej Kohli, Co-Founder of the Tej Kohli Foundation said:

“We started the Tej Kohli Foundation in 2005 with a project to provide daily meals for 1,000 children in Costa Rica. Since then the Tej Kohli Foundation has supported projects all over the world and helped tens of thousands of people, especially those living with disability. This gift of ten bionic arms is the first project that we have ever initiated in the UK. I see it as just the beginning, and my hope is that this gift will help to highlight the positive difference that technology can make to the confidence and prospects of a younger person. We’re doing this as an example, but we hope that others will follow our lead. These technologies are now so accessible and affordable that healthcare organisations such as the NHS should do more to embrace and improve access to them for disabled young people.”

Samantha Payne, Co-Founder and COO of Open Bionics said:

“We’re really grateful to the Tej Kohli Foundation for pledging to fund advanced bionic arms for ten children in the UK. These children are amongst dozens of people with upper limb differences in the UK fundraising right now for a Hero Arm. We've worked really hard to achieve a price point for the device that is acceptable for existing NHS budgets for prosthetic provision, and we very much hope the NHS sees how helpful these devices are and will begin offering them to the people who need them.”

Children and adults with below-elbow limb differences can register their interest at www.openbionics.com.

Images and profiles of the recipients of the Hero Arms can be downloaded here: https://www.dropbox.com/sh/wakjc66nz1ljjpb/AADwtFqgu7j-xhEtTRzYuBdsa?dl=0

About Open Bionics

Open Bionics was founded in 2014 by Joel Gibbard and Samantha Payne with the goal of developing affordable, assistive devices that enhance the human body. In other words, Open Bionics turns disabilities into superpowers. The Bristol-based bionics company is known globally for using 3D printing and 3D scanning, along with some clever software and design, to make advanced, affordable and accessible bionic limbs. In May 2018, the company released the Hero Arm, the world’s first medically approved 3D-printed bionic arm, and the very first multi-grip bionic arm for children as young as eight years old. The Hero Arm is available now through private prosthetic clinics all around the world. Open Bionics have a development contract with NHS England, with the aim of offering the Hero Arm on the NHS in the UK. They also have royalty-free licensing agreements with Disney, Marvel, Lucasfilm, Eidos Montreal and Twentieth Century Fox, making science fiction a reality.

http://www.openbionics.com

About the Tej Kohli Foundation

Founded in 2005, the Tej Kohli Foundation seeks to make interventions that transform individual lives. It is best known for its global mission to end corneal blindness, which disproportionately impacts young people in poorer countries. Since 2015 the Foundation has funded free corneal transplants in poor communities in India; and in 2019 the Foundation gifted $2m to Mass Eye and Ear in Boston, a teaching hospital of Harvard Medical School, to support the development of new technologies to cure blindness.

Through its ‘Impact Initiatives’ the Tej Kohli Foundation also makes direct interventions into the lives of young people whose confidence and prospects can be substantially improved. Previous ‘Impact Initiatives’ have included financial support for disabled children in Costa Rice, feeding schoolchildren at after-school clubs in poor communities, and also producing a short film to highlight the plight of young people in India living with a rare genetic disease.

http://www.tejkohlifoundation.com

About Tej Kohli

Tej Kohli is a London-based investor and philanthropist who first rose to success selling technology solutions and payments software during the dot com boom. His current focus is as a real estate investor within the world’s newly emerging technology hubs, and as a backer of high-impact AI, robotics and genomics ventures that have the potential to transform lives and change the world. He is also a major esports investor.

Tej Kohli is a distinguished Alumni of the Indian Institute of Technology in Kanpur (IITK) where he completed a degree in Electrical Engineering.

http://www.tejkohli.com

END

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

To request interviews please use the contact details below:
Helen Tarbet / Simon Compton / Kim van Beeck / Hannah Ratcliff
(Buchanan Communications)
kohliventures@buchanan.uk.com
+44 207 466 5000

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye